Phase 3 Study of the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine

Conditions: COVID-19 Interventions: Biological: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant; Biological: Novavax COVID-19 Vaccine; Biological: Comparator Influenza Vaccine - Fluarix; Biological: Comparator Influenza Vaccine -Fluarix High Dose; Biological: Placebo 0.9% sodium chloride for injection Sponsors: Novavax Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials